News
News
- Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
03/15/2022 / 00:32 - GlobeNewswire - AltruBio to Present at BioProcess International US West 2022
03/11/2022 / 14:00 - GlobeNewswire - DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer
03/10/2022 / 15:45 - GlobeNewswire - Rubicon Technologies to Participate in Upcoming Investor Conferences
03/10/2022 / 14:45 - GlobeNewswire - Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
03/10/2022 / 13:30 - GlobeNewswire - Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against C3.ai, Inc.
03/10/2022 / 02:00 - GlobeNewswire - Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
03/09/2022 / 14:21 - GlobeNewswire - Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
03/09/2022 / 13:00 - GlobeNewswire - Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
03/09/2022 / 07:30 - GlobeNewswire - INVESTOR NOTIFICATION: Kessler Topaz Meltzer & Check, LLP Announces Lead Plaintiff Deadline on April 25, 2022 in Securities Fraud Class Action Lawsuit Filed Against TaskUs, Inc.
03/09/2022 / 00:12 - GlobeNewswire
Real-time